vs
CareDx, Inc.（CDNA）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是CareDx, Inc.的1.4倍（$162.6M vs $117.7M），Ribbon Communications Inc.净利率更高（54.8% vs 2.4%，领先52.4%），CareDx, Inc.同比增速更快（39.0% vs -10.3%），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -8.1%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
CDNA vs RBBN — 直观对比
营收规模更大
RBBN
是对方的1.4倍
$117.7M
营收增速更快
CDNA
高出49.3%
-10.3%
净利率更高
RBBN
高出52.4%
2.4%
两年增速更快
CDNA
近两年复合增速
-8.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $162.6M |
| 净利润 | $2.8M | $89.1M |
| 毛利率 | — | 42.9% |
| 营业利润率 | — | — |
| 净利率 | 2.4% | 54.8% |
| 营收同比 | 39.0% | -10.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARBBN
| Q1 26 | $117.7M | $162.6M | ||
| Q4 25 | $108.4M | $227.3M | ||
| Q3 25 | $100.1M | $215.4M | ||
| Q2 25 | $86.7M | $220.6M | ||
| Q1 25 | $84.7M | $181.3M | ||
| Q4 24 | $86.6M | $251.4M | ||
| Q3 24 | $82.9M | $210.2M | ||
| Q2 24 | $92.3M | $192.6M |
净利润CDNARBBN
| Q1 26 | $2.8M | $89.1M | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | $-12.1M | ||
| Q2 25 | $-8.6M | $-11.1M | ||
| Q1 25 | $-10.4M | $-26.2M | ||
| Q4 24 | $87.7M | — | ||
| Q3 24 | $-10.6M | $-13.4M | ||
| Q2 24 | $-4.6M | $-16.8M |
毛利率CDNARBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 45.4% | ||
| Q4 24 | — | 55.7% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | — | 50.8% |
营业利润率CDNARBBN
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 4.1% | ||
| Q3 25 | -0.2% | 1.3% | ||
| Q2 25 | -12.8% | 1.9% | ||
| Q1 25 | -15.8% | -10.8% | ||
| Q4 24 | 97.5% | 13.2% | ||
| Q3 24 | -16.6% | -0.4% | ||
| Q2 24 | -7.9% | -1.0% |
净利率CDNARBBN
| Q1 26 | 2.4% | 54.8% | ||
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | -5.6% | ||
| Q2 25 | -9.9% | -5.0% | ||
| Q1 25 | -12.2% | -14.5% | ||
| Q4 24 | 101.3% | — | ||
| Q3 24 | -12.8% | -6.4% | ||
| Q2 24 | -5.0% | -8.7% |
每股收益（稀释后）CDNARBBN
| Q1 26 | $0.05 | $0.50 | ||
| Q4 25 | $-0.08 | $0.50 | ||
| Q3 25 | $0.03 | $-0.07 | ||
| Q2 25 | $-0.16 | $-0.06 | ||
| Q1 25 | $-0.19 | $-0.15 | ||
| Q4 24 | $1.60 | $0.05 | ||
| Q3 24 | $-0.20 | $-0.08 | ||
| Q2 24 | $-0.09 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $419.1M |
| 总资产 | $411.1M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARBBN
| Q1 26 | $77.9M | $67.6M | ||
| Q4 25 | $177.2M | $96.4M | ||
| Q3 25 | $194.2M | $74.8M | ||
| Q2 25 | $186.3M | $60.5M | ||
| Q1 25 | $230.9M | $71.2M | ||
| Q4 24 | $260.7M | $87.8M | ||
| Q3 24 | $240.9M | $37.2M | ||
| Q2 24 | $228.9M | $64.6M |
总债务CDNARBBN
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | $0 | $349.1M | ||
| Q2 24 | $0 | $350.0M |
股东权益CDNARBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $303.1M | $449.0M | ||
| Q3 25 | $311.1M | $360.1M | ||
| Q2 25 | $327.4M | $370.4M | ||
| Q1 25 | $379.3M | $381.8M | ||
| Q4 24 | $378.4M | $404.6M | ||
| Q3 24 | $273.2M | $395.5M | ||
| Q2 24 | $264.7M | $405.0M |
总资产CDNARBBN
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.2B | ||
| Q3 25 | $432.3M | $1.1B | ||
| Q2 25 | $444.3M | $1.1B | ||
| Q1 25 | $489.6M | $1.1B | ||
| Q4 24 | $491.1M | $1.2B | ||
| Q3 24 | $477.0M | $1.1B | ||
| Q2 24 | $466.8M | $1.1B |
负债/权益比CDNARBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | 0.00× | 0.88× | ||
| Q2 24 | 0.00× | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | — |
| 自由现金流经营现金流 - 资本支出 | $514.0K | — |
| 自由现金流率自由现金流/营收 | 0.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDNARBBN
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $29.2M | ||
| Q3 25 | $37.4M | $26.5M | ||
| Q2 25 | $9.9M | $-795.0K | ||
| Q1 25 | $-26.6M | $-3.5M | ||
| Q4 24 | $21.9M | $61.8M | ||
| Q3 24 | $12.5M | $-14.8M | ||
| Q2 24 | $18.9M | $-9.8M |
自由现金流CDNARBBN
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $27.3M | ||
| Q3 25 | — | $21.0M | ||
| Q2 25 | — | $-6.5M | ||
| Q1 25 | — | $-15.7M | ||
| Q4 24 | — | $53.8M | ||
| Q3 24 | — | $-23.7M | ||
| Q2 24 | — | $-12.9M |
自由现金流率CDNARBBN
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | -2.9% | ||
| Q1 25 | — | -8.7% | ||
| Q4 24 | — | 21.4% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | — | -6.7% |
资本支出强度CDNARBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.2% | ||
| Q2 24 | — | 1.6% |
现金转化率CDNARBBN
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
